AVISTA wishes you a happy Chinese New Year! May the Year of the Rat bring you good health and good fortune!
 
<img src="../../../../../uploads/AVISTA_CNY_Greetings_2020_c95d2827d4.png" width="700" />

stock-photo-cheers-people-celebrate-and-raise-glasses-of-wine-for-toast-group-of-man-and-woman-cheering-with-1573948762

Chinese New Year Greetings from AVISTA Group

AVISTA is pleased to be one of the participating companies, once again, in the Heep Yunn School Work Experience Placement Programme. From 4th to 7th of January 2022, four students from Heep Yunn School were assigned to work in AVISTA Hong Kong office full day to have a hands-on experience in the workplace and get to know about the day-to-day operations in the valuation and advisory industry. Pleased to be engaged in the programme and to make work immersion available, we hope to empower the younger generations to start building essential work skills that can help them make more informed career choices and improve their employment prospects.  <img src="../../../../../uploads/IMG_4054_349b0fd654.jpg" alt="" width="533" height="400" />

pinwheel-1716620_1920

As a Participating Company in Heep Yunn School Work Experience Placement Programme

Sirnaomics Ltd. has been successfully listed on the Mainboard of HKSE on 30 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. Sirnaomics is an RNA therapeutics biopharmaceutical company. Founded in 2007 in the U.S., the company is the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic. With research and development centers in both China and the U.S., the company delivers pre-clinical and clinical stage products and focuses on the discovery and development of innovative drugs. Sirnaomics’ core product STP705 demonstrated efficacy and safety in an oncology Phase I/II clinical trial for non-melanoma skin cancer. STP705 was further advanced in a Phase IIb clinical trial for squamous cell carcinoma in situ (isSCC), a Phase II clinical trial for treatment of skin basal cell carcinoma (BCC), a Phase II clinical trial for treatment of keloid and a Phase I/II clinical trial for treatment of hypertrophic scar (HTS). Sirnaomics has initiated a Phase I clinical trial using STP705 for treatment of liver cancer (basket) through a local injection based on an independent IND approval from US FDA. In addition, Sirnaomics will further optimize its drug delivery technology platforms and strengthen its capabilities to manufacture its products in large scale to promote the rapid growth of different clinical stage product lines they have currently and in the future. <img src="../../../../../uploads/EN_c93f3c2aa4.jpg" alt="" width="533" height="400" />

Congratulations to Sirnaomics Ltd. (2257.HK) on its Successful Listing

Focuslight Technologies Inc. (Focuslight) has been successfully listed on the Science and Technology Innovation Board (STAR) of the Shanghai Stock Exchange (SSE)on 24 December 2021. AVISTA Group is honored to be engaged in providing valuation services with regards to this listing application. Founded in 2007, Focuslight is primarily engaged in the upstream laser industry, focusing on research and development, production, and sale of high-power semiconductor laser components and laser optical components. Their products are used as solid-state laser pump sources and fiber laser core components, and in high-end industrial manufacturing, medical health and other fields. Focuslight is currently expanding their share in the midstream segment of the laser industry, setting foot in the development, production and sales of photonic application modules and systems, intelligent drive assistance systems, semiconductor integrated circuit chip manufacturing process, display panel manufacturing and other emerging application areas. <img src="../../../../../uploads/congrat_ad_EN_Focuslight_ce6c305244.JPG" alt="" width="533" height="400" />